Intestinal absorption and biliary secretion of cholesterol in rats with nephrotic syndrome.
BACKGROUND
Nephrotic syndrome (NS) results in hypercholesterolemia which is attributed to increased production and decreased removal of cholesterol-rich lipoproteins. Adjustments in intestinal absorption are reportedly involved in cholesterol homeostasis. We, therefore, studied the intestinal absorption and biliary excretion of cholesterol in NS.


METHODS
We studied intestinal absorption (by in vivo perfusion and in vitro everted sac incubation techniques) and biliary secretion (by common bile duct cannulation) of cholesterol in rats with puromycin-induced NS. The results were compared with those obtained from pair-fed control (PF) animals, those given free access to food (NL) or those fed a hypercholerolemic diet (H-chol group). Micellar solutions of Krebs' phosphate buffer containing trace amounts of [14C]inulin and [3H]cholesterol, as well as different concentrations of unlabeled cholesterol, were used for absorption studies.


RESULTS
The NS and H-chol groups showed severe and comparable hypercholesterolemia. No significant difference was found in the rate of biliary cholesterol secretion among the study groups. Likewise, the rates of in vivo and in vitro cholesterol absorptions in the NS and H-chol groups were comparable with one another and similar to those found in the NL and PF groups. The rate of in vitro cholesterol absorption was directly proportional to its concentration in the incubation media at low concentrations. However, the absorption rate showed a pattern consistent with saturable transport at high cholesterol concentrations in all groups.


CONCLUSIONS
We conclude that intestinal absorption and biliary secretion of cholesterol are not appreciably influenced by either nephrotic or diet-induced hypercholesterolemia in rats. The data further suggest that cholesterol absorption may be a saturable process.
Pahl
M V
MV
Department of Medicine, University of California, Irvine, USA.
Oveisi
F
F
Khamiseh
G
G
Vaziri
N D
ND
D000818:Animals; D001659:Biliary Tract / Q000378:metabolism*; D002791:Cholesterol, Dietary / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004195:Disease Models, Animal; D006937:Hypercholesterolemia / Q000209:etiology / Q000503:physiopathology; D066298:In Vitro Techniques; D007408:Intestinal Absorption; D008297:Male; D009404:Nephrotic Syndrome / Q000139:chemically induced / Q000150:complications / Q000503:physiopathology*; D010477:Perfusion; D011691:Puromycin / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley
D002791:Cholesterol, Dietary; D011691:Puromycin